Indivior Inc.
Quick facts
| Founded | 1994 |
|---|
Marketed products
- Buprenorphine (Subutex) · Psychiatry / Addiction Medicine
Buprenorphine is a partial opioid agonist that binds to mu-opioid receptors in the brain, reducing cravings and withdrawal symptoms while producing a lower risk of overdose compared to full opioid agonists. - PERSERIS
- SL Buprenorphine
- Suboxone · Other
- Suboxone Sublingual Film
- Subutex, Buprenorphine Hydrochloride, SCH 28444 · Psychiatry / Addiction Medicine
Buprenorphine is a partial mu-opioid receptor agonist that reduces cravings and withdrawal symptoms in opioid use disorder. - TM buprenorphine · Psychiatry / Addiction Medicine
Buprenorphine is a partial mu-opioid receptor agonist that binds with high affinity to reduce opioid cravings and withdrawal symptoms while producing a ceiling effect on respiratory depression. - Transmucosal Buprenorphine · Pain Management, Addiction Medicine
Buprenorphine is a partial mu-opioid receptor agonist that binds with high affinity to reduce opioid cravings and withdrawal symptoms while producing a ceiling effect on respiratory depression. - Zubsolv sublingual tablets · Psychiatry / Addiction Medicine
Zubsolv is a combination of buprenorphine and naloxone that binds to opioid receptors to reduce cravings and withdrawal symptoms in opioid use disorder.
Phase 3 pipeline
- RBP-6000 · Psychiatry / Substance Use Disorder
RBP-6000 is a subcutaneous depot formulation of buprenorphine that provides sustained opioid receptor partial agonism for extended periods. - RBP-7000 · Psychiatry
RBP-7000 is a subcutaneous depot formulation of risperidone that provides sustained antipsychotic activity through dopamine D2 receptor antagonism over an extended period.
Phase 2 pipeline
Phase 1 pipeline
- [14C]IDV184001AN
- Arbaclofen Placarbil IR
- Arbaclofen Placarbil MR Prototype A
- Arbaclofen Placarbil MR Prototype B
Arbaclofen placarbil is a prodrug that is converted to arbaclofen, a GABA-B receptor agonist that modulates neurotransmission in the central nervous system. - Arbaclofen Placarbil SR
- Buprenorphine Injectable Solution - Part A
- Buprenorphine Injectable Solution - Part B
- Fentanyl - Part A
- Fentanyl - Part B
- INDV-6200
- Nalorex · Other
- Oxycodone - Part B
Competitive intelligence
For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:
Frequently asked questions about Indivior Inc.
What are Indivior Inc.'s marketed drugs?
Top marketed products include Buprenorphine (Subutex), PERSERIS, SL Buprenorphine, Suboxone, Suboxone Sublingual Film, Subutex, Buprenorphine Hydrochloride, SCH 28444.
What is Indivior Inc.'s pipeline?
Indivior Inc. has 2 drugs in Phase 3, 6 in Phase 2, 12 in Phase 1. Late-stage candidates include RBP-6000, RBP-7000.
When was Indivior Inc. founded?
Indivior Inc. was founded in 1994.
Related
- Buprenorphine (Subutex) · Psychiatry / Addiction Medicine
- PERSERIS
- SL Buprenorphine
- Suboxone · Other
- Suboxone Sublingual Film
- Sector hub: All tracked pharma companies